Skip to content

An Exploratory Study for the Development of Information Medicine Using Inaudible High-Frequency Sound for Diabetes Treatment

An Exploratory Study for the Development of Information Medicine Using Inaudible High-Frequency Sound for Diabetes Treatment - Inaudible High-Frequency Sound Therapy for Diabetes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000058434
Enrollment
12
Registered
2025-07-11
Start date
2025-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes and Prediabetes

Interventions

Acoustic information containing high-frequency components beyond the upper limit of the audible range Acoustic information with only the high-frequency components removed from the same sound source

Sponsors

National Center of Neurology and Psychiatry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Individuals diagnosed with type 2 diabetes or prediabetes 2. Individuals who are currently receiving either pharmacotherapy, exercise therapy, or dietary therapy for the above condition 3. Male or female individuals aged 20 years or older and under 90 years

Exclusion criteria

Exclusion criteria: 1. Individuals diagnosed with type 1 diabetes 2. Individuals for whom participation in the study is considered difficult due to dementia, psychiatric disorders, or similar conditions 3. Individuals deemed inappropriate for participation by the attending physician or principal investigator

Design outcomes

Primary

MeasureTime frame
The time course of blood glucose levels will be continuously measured every 15 minutes using FreeStyle Libre before the intervention period, immediately after the start of the intervention, and just before the end of the intervention. Blood glucose fluctuations will be evaluated based on the area under the concentration-time curve (AUC) and the maximum blood concentration (Cmax); however, the calculation methods for these evaluation metrics themselves will also be a subject of investigation in this study.

Secondary

MeasureTime frame
HbA1c and fructosamine will be measured before, during, and after the intervention.

Countries

Japan

Contacts

Public ContactManabu Honda

National Center of Neurology and Psychiatry Department of Information Medicine, National Institute of Neuroscience

honda@ncnp.go.jp042-346-1718

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026